Kornimate/medical-research-clean huggingface dataset:
neurodynamics to improve jump functionality in trampoline jump gymnasts

Conditions: Athlete Foot

Summary: the goal of neurodynamics is to restore homeostasis of peripheral nerves. in the current context there is varied evidence that links neurodynamics with clinical pain treatments or different pathologies, but little evidence regarding changes in the functionality of athletes, which could be related to improvements in performance. the main objective of the study is to determine if the neurodynamic technique is effective in increasing the range of hip mobility and in increasing the jump with counter movement. randomized, simple blind clinical study. 15 trampoline jumping gymnasts will be randomized to the two study groups: experimental (active sciatic neurodynamics techniques) and control (without intervention). the intervention will last 4 weeks, with 3 weekly sessions of approximately 5 minutes each. the study variables will be the range of hip flexion movement (goniometry) and the countermove jump (my jump® application). a descriptive statistical analysis will be performed calculating the main statistical characteristics. the sample distribution will be calculated using a shapiro-wills analysis. the changes after each evaluation will be analyzed with the t-student test and with an anova of repeated measures the intra and intersubject effect will be observed. the effect size will be calculated using cohen's formula. it is intended to observe improvement in the range of hip flexion movement and in the jump with countermovement.


Eligibility criteria:
inclusion criteria: * trampoline jumping gymnasts * male * aged between 18 and 30 years * who train at least 2 days a week * federated in the madrid gymnastics federation exclusion criteria: * subjects who have a medical diagnosis of musculoskeletal pathology at the time of beginning the study * neural pathology in the last 6 months * with cognitive deficit that prevents them from understanding physical tests and questionnaires * have not signed the informed consent

Keywords: gymnastics trampoline neurodynamics jump range of motion randomized clinical trial
hyperbaric on pulmonary functions in post covid -19 patients.

Conditions: Post COVID-19 Patients

Summary: purpose of the study is to investigate the effect of hyperbaric oxygen on fvc, fev1 and on oxygen saturation in post-covid-19 patients, the effect of breathing exercises in form of diaphragmatic breathing exercise and pursed lip breathing with traditional medical treatment in form of (vitamin d, vitamin c and anticoagulation drugs on fvc, fev1 and on oxygen saturation in post-covid-19 patients.and the difference between the effect of hyperbaric and breathing exercises in form of diaphragmatic breathing exercise and pursed lip breathing with traditional medical treatment in form of (vitamin d, vitamin c and anticoagulation drugs on fvc, fev1 and on oxygen saturation in post-covid-19 patients seventy two covid-19 patients from both genders ranged in age chronology from twenty one to sixty six years will be conducted to participate in this study .selection of the study sample and evaluate of pulmonary functions improvement as well as hyperbaric oxygen therapy will be conducted at agriculture hospital in el mansoura town. the study sample will be divided randomly into two equal groups of(a\&b).all patients participated in the current study will receive breathing excesses in form of diaphragmatic breathing exercise and pursed lip breathing with traditional medical treatment in form of (vitamin d, vitamin c and anticoagulation drugs ,group a will receive 60 minutes of hbot(100%oxygen at 2 ata with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise. the body mass index (bmi) of each participated patient will be determined by measuring weight/ kg and height/ m2 using electronic weight and height scale to include bmi 25.0-29.9 kg/ . also using digital spirometer smp 21/01 rd (russian) for measuring of fvc parameters , to be less than 80% ,fev1 to be less than 80% and pulse oximeter for measuring oxygen saturation to range from 90%to 95% assessment will be done before and after treatment. the obtained results of this study will measure forced vital capacity (fvc), forced expiratory volume (fev1) and oxygen saturation to determine the significant improvement of participated patients.


Eligibility criteria:
inclusion criteria * 1. post covid -19 patients (2weeks after recovery). 2.post covid -19 patients with deficiency in forced vital capacity (less than 80%) forced expiratory volume (less than 80%) lower oxygen saturation (90%-95%). 3.age (21-66)years old. 4.both gender. 5.bmi 25.0-29.9. exclusion criteria: 1. copd or other respiratory diseases. 2. neurological disease. 3. mental illness. 4. critically ill patients with intubation. 5. smokers. 6. inner ear diseases. 7. pregnancy.
novel quantification methods for fluorescence to detect progression in stargardt disease

Conditions: Stargardt Disease

Summary: the purpose of this study is to utilize flavoprotein fluorescence and fundus autofluorescence to detect progression of stargardt macular dystrophy in a pediatric population over the course of a year with the hope of aiding future therapeutic risk-benefit decisions and assessment of outcomes. stargardt macular dystrophy is the most common of the juvenile-onset macular dystrophies. despite determination of abca4 as the causative gene, clinicians have been challenged by variability in clinical phenotypes. given the recent initiation of clinical trials to assess novel treatments (e.g. gene therapy), there is a need to identify patients with the worst prognosis. the investigators have observed that pediatric patients lose central visual function faster than their adult counterparts. thus, they present an ideal cohort with which to determine the utility of novel modalities to detect early change. these include flavoprotein fluorescence, a new imaging technique for detecting mitochondrial dysfunction developed at the university of michigan. fundus autofluorescence (faf) is another commonly utilized technique of evaluating hereditary eye diseases. the investigators have developed a novel means of quantifying faf signatures that will allow documentation of severity as well as detection of progression.

this study will evaluate whether more sophisticated testing and analytic methodologies, including fundus autofluorescence (faf) and a novel non-invasive method to measure retinal flavoprotein fluorescence (fpf) may be used to better predict stargardt macular dystrophy progression and monitor treatment effects than conventional modalities such visual acuity and visual field. this method involves the use of novel statistical methods to assess the heterogeneity of fundus autofluorescence images. participants will complete 3 visits to the university of michigan kellogg eye center. each visit will take approximately 2.5 hours. the initial visit will include a routine clinical eye examination, measurement of best-corrected visual acuity, indirect ophthalmoscopy, microperimetry, frequency-domain optical coherence tomography, goldmann visual fields, fundus flavoprotein fluorescence (fpf) imaging, and fundus autofluorescence (faf) and fundus photography. patients will return for evaluation at 6 and 12 months after their initial visit to repeat testing and imaging.

Eligibility criteria:
inclusion criteria: * between the age of 5 and 18 years old * clinical diagnosis of stargardt disease * molecular confirmation of stargardt disease (with 2 identified mutations in abca4) * visual acuity better than 20/100 exclusion criteria: * limited central vision, defined as visual acuity worse than 20/100 * a diagnosis of any other retinal degenerative disease

Keywords: stargardt disease macular degeneration retinal dystrophy
preeclampsia associated vascular aging

Conditions: Pre-Eclampsia

Summary: to evaluate cardiovascular health, especially endothelial health, of women after pre-eclampsia compared to women without pre-eclampsia, and to compare women who had taken petn during pregnancy with women who had not attempted treatment

the clinical observation that women with pre-eclampsia have a high risk of early onset cardiovascular disease with increased disease-associated mortality has led to the hypothesis that the endothelial status of these women is characterized by early onset of aging. we want to investigate the relationship between endothelial aging and pregnancy disorders such as pre-eclampsia, which are dominated by endothelial dysfunction. do endothelial changes precede pregnancy and cause pre-eclampsia and later accelerated cardiovascular aging, or does pre-eclampsia trigger premature endothelial aging in affected individuals for the first time? the aim of this study is to investigate the cardiovascular health of women 10 to 20 years after pre-eclampsia and to compare it with that of women with uneventful pregnancies. in addition, the potential long-term endothelial protective effect of the no-donor pentaerithrityltetranitrate (petn) is investigated. this in vivo study will be extended in vitro by the analysis of senescence induction in endothelial cells after pre-eclampsia associated stress. additionally, the potential protective effect of petn on stress-induced senescence will be evaluated. the ultimate goal is to establish a prospective long-term study on the effect of petn on vascular health in women with pre-eclampsia to assess whether treatment of endothelial dysfunction during pregnancy could reduce endothelial aging and thus premature cardiovascular morbidity and mortality in millions of women.

Eligibility criteria:
inclusion criteria: * participants of the petn pilot study from 2002-2008 * controls: uneventful pregnancies from 2002-2008 * patients with pre-eclampsia with petn treatment 10-20 years ago * controls: patients with pre-eclampsia without petn treatment 10-20 years ago * written informed consent * singleton pregnancy exclusion criteria: * patients who refuse to participate in the study * impossibility of the outpatient presentation
effectiveness and safety study for jnj-18054478 in asthma patients.

Conditions: Asthma

Summary: the purpose of this study is to assess the effectiveness of jnj-18054478 measured by the percent change from baseline in forced expiratory volume in one second (fev1) after 12 weeks of therapy in patients with persistent asthma.

asthma is one of the most common chronic diseases worldwide. this is a randomized (study medication assigned by chance), double-blind study (neither the physician or the patient knows which drug they are receiving, active or placebo) to investigate the effectiveness and safety of 12 weeks of dosing with jnj-18054478 (300 mg taken orally once daily) compared with placebo in patients with persistent asthma. the hypothesis is that the study drug will be more effective in treatment of asthma than placebo as measured by the percent change from baseline in forced expiratory volume in one second (fev1) after 12 weeks of therapy, without any significant adverse events. safety evaluations will include, monitoring for adverse reactions, clinical laboratory tests of blood and urine, ecgs to monitor the cardiovascular system, vital signs and physical examinations. patients will take three capsules (100 mg) of jnj-18054478 orally once daily for 12 weeks or placebo for the same period.

Eligibility criteria:
inclusion criteria: * medically confirmed diagnosis of persistent asthma * able to demonstrate reversibility of at least 12% with albuterol inhalation * use of short-acting b-2 agonists for rescue \>= 5 times within 2 weeks prior * able to produce an fev1 between 45 and 85% of predicted * willing to perform study procedures for about 14 weeks. exclusion criteria: * use of inhaled corticosteroids within 4 weeks * use of oral/parenteral corticosteroids within 8 weeks * use of long-acting beta-2 agonists or montelukast within 2 weeks * history of life-threatening asthma attack within 3 months * female of child bearing potential.

Keywords: asthma persistant asthma controller medications fev1
randomized multicenter study comparing docetaxel plus cisplatin and 5-fu to cisplatin plus 5-fu in advanced gastric cancer

Conditions: Stomach Neoplasm

Summary: phase ii: primary objective: to select one of the 2 test arms (docetaxel with cisplatin, docetaxel with cisplatin and 5-fu), based primarily on complete responses, to advance to a phase iii survival comparison against the cddp + 5-fu control arm. secondary objective: to evaluate the quantitative and qualitative safety profile of the 2 test groups. phase iii: primary objective: to detect a statistically significant increase in time to progression (ttp) for the test arm (docetaxel plus cisplatin and 5-fu) relative to the control arm (cisplatin plus 5-fu). main secondary objective: to detect a statistically significant increase in overall survival (os) for the test arm (docetaxel plus cisplatin and 5-fu) relative to the control arm (cisplatin plus 5-fu). other secondary objectives: to compare response rates, time to treatment failure, duration of response, safety profiles, quality of life and disease-related symptoms.socio-economic data will be collected in order to be able to perform an analysis by country when necessary.


Eligibility criteria:
inclusion criteria: * patient's consent form obtained, signed and dated before beginning specific protocol procedures. * gastric adenocarcinoma including adenocarcinoma of the esophagogastric junction, histologically proven. * measurable and/or evaluable metastatic disease; if a single metastatic lesion is the only manifestation of the disease, cytology or histology is mandatory. locally recurrent disease is accepted provided that there is at least one measurable lesion (e.g. lymph node). * performance status karnofsky index \> 70%. * life expectancy of more than 3 months. * adequate haematological and biochemistry parameters * no prior palliative chemotherapy, previous adjuvant (and/or neo-adjuvant) chemotherapy is allowed if more than 12 months has elapsed between the end of adjuvant (or neo-adjuvant) therapy and first relapse. exclusion criteria: * pregnant or lactating women. * patients (m/f) with reproductive potential not implementing adequate contraceptive measures. * other tumor type than adenocarcinoma (leiomyosarcoma ; lymphoma). * any prior palliative chemotherapy. prior adjuvant (and/or neo-adjuvant) chemotherapy with a first relapse within 12 months from the end of adjuvant (or neo-adjuvant). * prior treatment with taxanes. prior cddp as adjuvant (and/or neo-adjuvant) chemotherapy with cumulative dose \> 300 mg/m².

Keywords: docetaxel stomach neoplasm
a phase 2 study on effect of thymosin beta 4 on wound healing in patients with epidermolysis bullosa

Conditions: Epidermolysis Bullosa

Summary: the purpose of this study is to investigate a treatment to enhance the healing of acute and chronic nonhealing cutaneous wounds, such as the erosions experienced by patients with epidermolysis bullosa (eb), by the known activity of thymosin beta 4 (tβ4). funding source - fda office of orphan product development (oopd).

eb is a group of genetic diseases characterized by skin-blistering and lesion-formation after minor trauma to the skin. this family of disorders, most of which are inherited, range in severity from mild to the severely disabling and life-threatening. tβ4 is a synthetically-produced copy of a naturally-occurring 43 amino acid peptide that has wound healing and anti-inflammatory properties and can up-regulate the expression of laminin-5.

Eligibility criteria:
inclusion criteria: * informed consent form signed by the patient or patient's legal representative; also, if the patient is under the age of majority but capable of providing assent, signed assent from the patient * diagnosis of junctional or dystrophic eb. * patients who present with hallopeau-siemens subtype may be enrolled. * at least one active, unroofed eb erosion on the limb or on the trunk. * lesion size 5 to 50 cm2, inclusive. * stable lesion present for 14-60 days before enrollment. * more that one member in a family can be enrolled as long as that member is treated to a different cohort with an assurance that the study medication will not be shared. * no clinically significant abnormalities (grade 2 or higher on the national cancer institute \[nci\] toxicity scale) on screening laboratory tests, except for the following specific laboratory threshold result: albumin must be 2 g/dl or higher; hemoglobin must be 8 g/dl or higher. exclusion criteria: * clinical evidence of local infection of the index (targeted) lesion. * use of any investigational drug within the 30 days before enrollment. * use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment. * use of systemic or topical steroidal therapy within the 30 days before enrollment.inhaled steroids are allowed. * use of systemic antibiotics within the 7 days before enrollment. * current or former malignancy. * arterial or venous disorder resulting in ulcerated wounds. * diabetes mellitus. * pregnancy or breastfeeding during the study. (a serum pregnancy test will be performed at screening for female patients of childbearing potential.)

Keywords: epidermolysis bullosa cutaneous wound-healing chronic wound-healing thymosin beta 4 laminin-5
prospective validation of the prognostic value of long non-coding mfi2-as1 rna in localized clear cell kidney cancers

Conditions: Kidney Cancer

Summary: an exploratory analysis of the expression of mfi2-as1 will be performed at the plasma level with the objective of comparing this expression with tumor tissue. the objective would be to be able to use long non-coding rna as a biomarker for diagnosis before tissue analysis and for patient follow-up. in addition, correlations will be made between tumor expression of mfi2-as1 and genetic and immune alterations in tumors in order to better clarify the link between the expression of this long non-coding rna and the characteristics of the tumor and of the tumor. tumor microenvironment.


Eligibility criteria:
inclusion criteria: * adult patient * localized kidney tumors\> t1a * patient having signed an informed consent * patient affiliated to a health insurance plan * subject having signed a consent form to participate in research and the constitution of a collection and genetic analyzes exclusion criteria: * metastatic carcinoma from the outset * contraindication to performing a tap ct with injection of contrast product * inability to provide informed information about the subject (subject in an emergency situation, difficulties in understanding, etc.) * subject under legal protection * subject under tutorship or curatorship * pregnancy * feeding with milk
functional and occupational rehabilitation of troops

Conditions: Chronic Musculoskeletal Pain

Summary: the proposed implementation science project will evaluate the factors that support or hinder the successful implementation of the fort functional restoration program at six military treatment facilities (mtf) across the military health system. it will also evaluate the associated effectiveness outcomes related to chronic musculoskeletal pain management in active-duty military personnel.

this project will be an effectiveness-implementation hybrid type 2 study design using a stepped-wedge randomized clinical trial research design. the study will simultaneously evaluate clinical and implementation outcomes related to the establishment of functional restoration programs. the study investigators have collaborated with the defense health agency (dha) pain management clinical support services to identify chronic pain management programs at six mtfs interested in systematically improving and assessing the outcomes of their program. the mtfs will be randomized in pairs to initiate the implementation facilitation strategy to improve the implementation of their program over three 6-month intervals, after an initial 6-month baseline. this hybrid design will allow for the evaluation of both implementation and clinical effectiveness research aims and support rapid translation of research outcomes. each site will participate in a minimum 6-month baseline period prior to the intervention period to serve as its own treatment as usual.

Eligibility criteria:
inclusion criteria: "patient referred to functional restoration program by provider" exclusion criteria: "patient not referred to functional restoration program by provider"
antibiotics after breast reduction:clinical trial with randomization

Conditions: Surgical Site Infection

Summary: this study was designed to determine the role of antibiotics reduction mammaplasty influence surgical site infections rates.

prevention of ssi is important due to its morbidity, longer hospital stays and higher costs. in many surgical procedures where the risk of infection is relatively low and the postoperative infection can be treated properly, the role of antibiotics is not clear. despite the lack of evidence from prospective randomized controlled trials of evaluation, the use of antibiotics in plastic surgery is widespread in order to offer the highest safety standards patients. the breast reduction is defined as "clean surgery" with a lower infection rate to 3.4%. thus, the antibiotic is not recommended. however, studies have shown a real rate of infection associated with procedures ranging from 4-36%. thus, this trial was designed to verify the role of antibiotics in reduction mammaplasty.

Eligibility criteria:
inclusion criteria: * breast hypertrophy * body mass index between 19 to 30 kg/m2 exclusion criteria: * patients undergoing a surgical procedure in the breast * diagnosis of breast pathology * smoking * childbirth or lactation less than a year * uncontrolled comorbidities * use of immunosuppressive drugs * misuse of capsules supplied * absence during the weekly follow-up

Keywords: plastic surgery mammaplasty wound infection prophylaxis